January 2020 Approvals: Medtronic And Abbott Announce DBS Approvals
Executive Summary
January’s new medical device approvals include the US FDA approval of a new indication for Abbott’s Infinity deep brain stimulation system and a CE mark for Abbott’s Tendyne transcatheter mitral valve replacement system. Medtronic also announced CE marks for a new line of implantable defibrillators and resynchronization devices as well as a CE mark for its Percept PC neurostimulator.
You may also be interested in...
Cardiovascular Sales & Earnings Roundup: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019
The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.
Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark
Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.